Skip to main content

Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses

Publication ,  Conference
Kasper, B; Federman, N; Reichardt, P; Attia, S; Lim, A; Amoruccio, V; Cho, S; Riedel, RF
Published in: JOURNAL OF CLINICAL ONCOLOGY
2024

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2024

Volume

42

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kasper, B., Federman, N., Reichardt, P., Attia, S., Lim, A., Amoruccio, V., … Riedel, R. F. (2024). Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Kasper, Bernd, Noah Federman, Peter Reichardt, Steven Attia, Allison Lim, Vincent Amoruccio, Sunny Cho, and Richard F. Riedel. “Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.
Kasper B, Federman N, Reichardt P, Attia S, Lim A, Amoruccio V, et al. Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.
Kasper B, Federman N, Reichardt P, Attia S, Lim A, Amoruccio V, Cho S, Riedel RF. Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses. JOURNAL OF CLINICAL ONCOLOGY. 2024.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2024

Volume

42

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences